POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the principal intracellular cation; it restores normal potassium levels, essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose provides calories, and sodium chloride corrects electrolyte deficits; the combination maintains osmotic pressure.
| Metabolism | Potassium is not metabolized; it is excreted primarily by the kidneys. Dextrose is metabolized via glycolysis and the Krebs cycle. Sodium chloride is excreted renally. |
| Excretion | Renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%). |
| Half-life | Potassium has no true terminal half-life as it is homeostatically regulated; the plasma disappearance half-life after IV administration is approximately 1-2 hours, reflecting rapid cellular uptake, but steady-state redistribution in total body stores takes days. |
| Protein binding | Potassium is not significantly protein-bound (<2%), as it exists as free ion K+. |
| Volume of Distribution | Approximately 0.5-0.6 L/kg (total body water), reflecting distribution throughout extracellular and intracellular spaces; clinical meaning: large Vd indicates extensive tissue uptake, primarily into muscle. |
| Bioavailability | Oral: 100% (but potassium is rapidly absorbed and distributed); IV: 100%. |
| Onset of Action | IV: Immediate (within minutes) for serum potassium elevation; oral: 30-60 minutes for measurable serum increase. |
| Duration of Action | IV: Effect lasts 2-4 hours after a single dose, but redistribution continues; oral: effect persists 4-6 hours; clinical duration depends on ongoing losses and intracellular shifts. |
| Molecular Weight | 74.55 |
10-40 mEq potassium chloride in 1000 mL D5 0.225% NaCl, intravenous infusion at a rate not exceeding 10 mEq/hour and 200 mEq/24 hours.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25-50%; GFR <30 mL/min: contraindicated or use with extreme caution, reduce dose by 50-100%. |
| Liver impairment | No specific guidelines; use standard dosing with monitoring of potassium levels. |
| Pediatric use | 0.5-1 mEq/kg/dose IV, not to exceed 40 mEq per dose, maximum infusion rate 0.5-1 mEq/kg/hour. |
| Geriatric use | Initiate at lower end of dosing range (10-20 mEq/24 hours), titrate based on renal function and potassium levels, maximum infusion rate 5-10 mEq/hour. |
| 1st trimester | Potassium chloride is generally considered safe in pregnancy when used at recommended doses. Normal maternal potassium homeostasis is critical for fetal development; however, excessive doses may cause maternal hyperkalemia with potential fetal effects. Use only if clearly needed and monitor serum potassium. |
| 2nd trimester | Same as T1. Maintain normal potassium levels for maternal and fetal health. Monitor serum potassium to avoid hyperkalemia. |
| 3rd trimester | Same as T1 and T2. Potassium chloride is commonly used in parenteral nutrition and fluid therapy during labor and delivery. No known teratogenic risk at therapeutic doses. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium crosses the placenta passively and is regulated by maternal-fetal gradients. Transfer is significant; fetal serum potassium correlates with maternal levels. No specific molecular mechanism for active transport, but placental handling maintains fetal potassium homeostasis. |
| Breastfeeding | Potassium is a normal constituent of breast milk. Exogenous potassium from supplements or IV fluids increases milk potassium concentration minimally. No adverse effects in breastfed infants are expected at maternal therapeutic doses. Use with caution only if maternal serum potassium is monitored to avoid hyperkalemia. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride is not teratogenic. No increased risk of congenital anomalies reported. Use during pregnancy is considered safe with appropriate monitoring for electrolyte imbalance. Trimester-specific risks are not applicable as potassium chloride is a physiological electrolyte. |
| Fetal Monitoring | Monitor maternal serum potassium levels, renal function, ECG, and fluid status. In pregnancy, monitor for signs of hyperkalemia: paresthesias, muscle weakness, arrhythmias. Fetal monitoring as per gestational age, not specifically for potassium. |
| Fertility Effects | No known effect on fertility. Potassium chloride is an electrolyte replacement, not associated with reproductive toxicity. |
■ FDA Black Box Warning
Concentrated potassium solutions must be diluted before administration; improper dilution or rapid infusion may cause cardiac arrest or fatal arrhythmias.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaConcurrent use with potassium-sparing diuretics or ACE inhibitors with elevated potassiumSevere metabolic acidosis (unless corrected)Adrenal insufficiencyAcute dehydrationCellular lysis states (e.g., massive hemolysis, rhabdomyolysis)
| Precautions | Monitor serum potassium levels and ECG during therapy, Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia, Risk of hyperkalemia if potassium is administered too rapidly or in excessive amounts, Avoid in patients with severe renal failure unless dialysis is available, Do not use in patients with hyperkalemia, Cardiotoxicity may occur if potassium is administered in patients with digitalis toxicity |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados, dried fruits) to prevent hyperkalemia. Avoid salt substitutes that contain potassium chloride. Limit foods high in sodium unless directed by physician. |
| Clinical Pearls | For peripheral IV administration, maximum infusion rate is 10 mEq/hr (0.5 g/hr) via central line; 20 mEq/hr via peripheral line may cause phlebitis. Avoid in patients with severe renal impairment (GFR <30 mL/min) or hyperkalemia. Monitor serum potassium and ECG continuously during infusion. Use with caution in patients receiving digoxin, ACE inhibitors, or ARBs. Do not administer undiluted; fatal cardiac arrhythmias may occur. Verify patency of IV line before infusion to avoid extravasation. |
| Patient Advice | This medication is a combination of potassium, sugar, and salt water given through a vein to correct low potassium levels. · Report immediately any pain, redness, or swelling at the injection site, chest pain, irregular heartbeat, or muscle weakness. · Do not consume potassium supplements or salt substitutes containing potassium while receiving this medication without talking to your doctor. · Tell your doctor if you have kidney disease, heart disease, or are on medications like ACE inhibitors or diuretics. · This medication may affect your blood sugar; monitor if you are diabetic. · You may need regular blood tests to check potassium and other electrolyte levels. |
Loading safety data…